One interesting example, specifically for treatment of TDP-43 proteinopathies, is ASO therapy to correct mis-processing of STMN2 pre-mRNA which occurs as a result of nuclear loss of TDP-43 in disease. This evidence concerns the gene TARDBP and proteostasis deficiencies.